2. Search Result
Search Result
Results for "

RARα

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156280
    RARα antagonist 1

    		RAR/RXR Endocrinology
    RARα antagonist 1 (compound 21) is an orally active and selective retinoic acid receptor α(RARα) antagonist, with the IC50 of 4.6nM .
    RARα antagonist 1
  • HY-153122A
    YCT529

    		RAR/RXR Endocrinology
    YCT529 is a potent, selective and orally active RAR-α inhibitor .
    YCT529
  • HY-14653
    Amsilarotene

    TAC-101; Am 555S

    		 RAR/RXR Apoptosis Cancer
    Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with Ki of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer .
    Amsilarotene
  • HY-107397
    Ch55
    2 Publications Verification

    		 RAR/RXR Cancer
    Ch55 is a potent synthetic retinoid. Ch55 binds to RAR-α and RAR-β receptors with high affinity. Ch55 displays low affinity for cellular retinoic acid binding protein (CRABP). Ch55 is a potent inducer of the differentiation of HL60 cells with an EC50 of 200 nM. Ch55 can be used for cancer research .
    Ch55
  • HY-107436
    LE135
    1 Publications Verification

    		 RAR/RXR TRP Channel Neurological Disease Cancer
    LE135 is a potent RAR antagonist that binds selectively to RARα (Ki of 1.4 μM) and RARβ (Ki of 220 nM), and has a higher affinity to RARβ. LE135 is highly selective over RARγ, RXRα, RXRβ and RXRγ. LE135 is also a potent TRPV1 and TRPA1 receptors activator with EC50s of 2.5?μM and 20?μM, respectively .
    LE135
  • HY-B0091
    Adapalene
    4 Publications Verification

    CD271

    		 RAR/RXR Autophagy Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Adapalene (CD271), a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene is a potent RAR agonist, with AC50s of 2.3 nM, 9.3 nM, and 22 nM for RARβ, RARγ, RARα, respectively. Adapalene also inhibits the enzymatic activity of GOT1 in a non-competitive manner. Adapalene exhibits anti-tumor activity .
    Adapalene
  • HY-108531
    ER 50891

    		RAR/RXR Cancer
    ER-50891 is a potent antagonist of retinoic acid receptor α(RARα). ER-50891 significantly attenuates ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis .
    ER 50891
  • HY-153122
    YCT529 free acid

    		RAR/RXR Endocrinology
    YCT529 free acid is a potent, selective and orally active RAR-α inhibitor .
    YCT529 free acid
  • HY-107218
    11-Hydroxysugiol

    		RAR/RXR VD/VDR Infection
    11-Hydroxysugiol regulates the SUMOylation of intracellular receptors by modulating RARα and vitamin D3 receptor (VDR) .
    11-Hydroxysugiol
  • HY-B0091A
    Adapalene sodium salt

    CD 271 sodium salt

    		 RAR/RXR Autophagy Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Adapalene (CD271) sodium salt, a third-generation synthetic retinoid, is widely used for the research of acne. Adapalene sodium salt is a potent RAR agonist, with AC50s of 2.3 nM, 9.3 nM, and 22 nM for RARβ, RARγ, RARα, respectively. Adapalene sodium salt also inhibits the enzymatic activity of GOT1 in a non-competitive manner. Adapalene sodium salt exhibits anti-tumor activity .
    Adapalene sodium salt
  • HY-119518
    BMS641

    BMS-209641

    		 RAR/RXR Cancer
    BMS641 (BMS-209641) is a selective RARβ agonist. BMS641 has a higher affinity for RARβ (Kd, 2.5 nM) that is 100 times higher than that for RARα (Kd, 225 nM) or RARγ (Kd, 223 nM) .
    BMS641
  • HY-116248
    Ro 41-5253

    		RAR/RXR Apoptosis Cancer
    Ro 41-5253 is an orally active selective retinoic acid receptor alpha (RARα) antagonist. Ro 41-5253 can bind RARα without inducing transcription or affecting RAR/RXR heterodimerization and DNA binding. Ro 41-5253 can inhibit cancer cell proliferation and induce apoptosis, has antitumor activity .
    Ro 41-5253
  • HY-108531A
    ER 50891 quarterhydrate

    		RAR/RXR Cancer
    ER 50891 quarterhydrate is a potent antagonist of retinoic acid receptor α(RARα). ER 50891 quarterhydrate significantly attenuates ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis .
    ER 50891 quarterhydrate
  • HY-100608
    BMS453
    1 Publications Verification

    BMS-189453

    		 RAR/RXR Cancer
    BMS453 (BMS-189453), a synthetic retinoid, is a RARβ agonist and a RARα/RARγ antagonist. BMS453 inhibits breast cell growth predominantly through the induction of active TGFβ .
    BMS453

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: